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Abstract
Background: Stroke is one of the leading causes of death worldwide and a major cause of
morbidity and mortality in the United States of America. Brain ischemia-reperfusion (IR) triggers a
complex series of biochemical events including inflammation. Leukotrienes derived from 5-
lipoxygenase (5-LOX) cause inflammation and are thus involved in the pathobiology of stroke
injury.
Methods: To test the neuroprotective efficacy of 5-LOX inhibition in a rat model of focal cerebral
IR, ischemic animals were either pre- or post-treated with a potent selective 5-LOX inhibitor, (N-
[3-[3-(-fluorophenoxy) phenyl]-1-methyl-2-propenyl]-N-hydroxyurea (BW-B 70C). They were
evaluated at 24 h after reperfusion for brain infarction, neurological deficit score, and the
expression of 5-LOX. Furthermore, the mechanism and the anti-inflammatory potential of BW-B
70C in the regulation of nuclear factor kappa B (NF-κB) and inflammatory inducible nitric oxide
synthase (iNOS) were investigated both in vivo and in vitro.
Results and discussion: Both pre- and post-treatment with BW-B 70C reduced infarctions and
improved neurological deficit scores. Immunohistochemical study of brain sections showed IR-
mediated increased expression of 5-LOX in the neurons and microglia. BW-B 70C down-regulated
5-LOX and inhibited iNOS expression by preventing NF-κB activation. Two other structurally
different 5-LOX inhibitors were also administered post IR: caffeic acid and 2, 3, 5-trimethyl-6- [12-
hydroxy-5, 10-dodecadiynyl]-1, 4-benzoquinone (AA-861). As with BW-B 70C, they provided
remarkable neuroprotection. Furthermore, in vitro, BW-B 70C inhibited lipopolysaccharide (LPS)
mediated nitric oxide production, iNOS induction and NF-κB activation in the BV2 microglial cell
line. Treating rat primary microglia with BW-B70C confirmed blockage of LPS-mediated
translocation of the p65 subunit of NF-κB from cytosol to nucleus.
Conclusion: The study demonstrates the neuroprotective potential of 5-LOX inhibition through
down-regulation of NF-κB in a rat model of experimental stroke.
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Cerebral ischemia-reperfusion (IR) triggers lipid peroxida-
tion and inflammation, which exacerbate injury. Recogni-
tion of inflammatory components involved in stroke has
expanded the list of potential targets for therapy [1]. They
include inducible nitric oxide synthase (iNOS), cyclooxy-
genase-2 (COX-2), nuclear factor kappa B (NF-κB) and 5-
lipoxygeanse (5-LOX) [2,3]. 5-LOX is the key enzyme in
leukotriene biosynthesis [4]. It translocates to the nuclear
membrane upon stimulation, where it co-localizes with 5-
LOX activating protein (FLAP) and cytosolic phospholi-
pase A2 (cPLA2) [5]. This event converts arachidonic acid
to leukotrienes. Emerging data implicate both 5-LOX and
FLAP in the disease process of cerebral ischemia [6].
Increased leukotriene levels and 5-LOX expression have
been documented in stroke patients [7]. Also, FLAP has
recently been identified as the first common gene associ-
ated with higher risk in atherosclerosis and stroke [8].
5-LOX-mediated reactive oxygen species (ROS) genera-
tion has been implicated in the activation of NF-κB [9,10].
Recently, we have demonstrated that PLA2 and 5-LOX are
involved in lipopolysaccharide (LPS)-induced iNOS gene
expression via dependent and independent NF-κB path-
ways in glial cells [11]. NF-κB is an important transcrip-
tion factor that plays a pivotal role in mediating
inflammatory response to pro-inflammatory cytokines
and ROS in animal models of experimental stroke
[10,12]. In unstimulated cells, p50:p65 is sequestered in
the cytoplasm by inhibitory proteins known as NF-κB
inhibitors (IκBs). Upon stimulation, IκB is phosphor-
ylated by an upstream IκB kinase (IKK), which leads to its
ubiquitination and proteosomal degradation. This proc-
ess liberates p50:p65, which translocates to the nucleus
and induces transcription of several genes, including
iNOS. In ischemia, the p65 subunit is recognized to play
an important role in regulation of inflammation [13]. It
has also been shown that P65 interaction with 5-LOX acti-
vates NF-κB [14].
In the present study, we used a 5-LOX inhibitor, N- [3-[3-
(-fluorophenoxy) phenyl]-1-methyl-2-propenyl]-N-
hydroxyurea (BW-B 70C), in a rat model of focal cerebral
IR. BW-B 70C demonstrated a neuroprotective role
through inhibition of both 5-LOX and NF-κB. It is a
potent and a selective inhibitor of 5-LOX in vitro and in
vivo with a long half-life and high oral bioavailability.
Other potent 5-LOX inhibitors, caffeic acid and 2, 3, 5-tri-
methyl-6- [12-hydroxy-5, 10-dodecadiynyl]-1, 4-benzo-
quinone (AA-861) confirmed the neuroprotective efficacy
of 5-LOX inhibition. A similar protective effect of AA-861
has been reported in gerbils after transient ischemia [15].
Our observations document that 5-LOX inhibition pro-
tects against IR injury in rats via down-regulation of the
inflammatory mediators NF-κB and iNOS. Thus, inhibit-
ing the 5-LOX/NF-κB pathway holds therapeutic potential
to attenuate inflammation-mediated brain injury after an
ischemic stroke.
Methods
Reagents and cell culture
Dulbecco's Modified Eagle's Medium (DMEM) with glu-
cose, L-glutamine and sodium pyruvate was purchased
from Mediatech Inc. (Herndon, VA), Fetal Bovine Serum
(FBS) and Hank's balanced salt solution were obtained
from Life Technologies (Carlsbad, CA). Lipopolysaccha-
ride (LPS; 0111:B4)) from Escherichia coli, and MTT (3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide) were obtained from Sigma-Aldrich Chemical Cor-
poration (St. Louis, MO). Antibody against 5-LOX was
purchased from Cayman Chemical (Ann Arbor, Michi-
gan). Antibody against p65, p50, iNOS, NSE and β-actin
were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), and RCA-1, (ricinus communis aggluti-
nin-1) was purchased from Vector Laboratories, (Burlin-
game, CA). Anti-cow GFAP was purchased from
DakoCytomation California Inc. (Carpinteria, CA). BW-B
70C was purchased from Tocris (Ellisville, MO). Caffeic
acid and AA-861 were purchased from Biomol (Plymouth
Meeting, PA). The enhanced chemiluminescence (ECL)
detecting reagent was from Amersham Pharmacia Biotech
(Arlington Heights, IL), and the luciferase assay system
was from Promega (Madison, WI,). NF-κB-luciferase
chemiluminescence kit was purchased from Clontech
(Palo Alto, CA). IQ Sybr Green Supermix was purchased
from Bio-Rad (Hercules, CA).
Animals
Male Sprague-Dawley rats weighing 240–260 g (Harlan
Laboratories, Wilmington, MA) were used in this study.
All animal procedures were approved by the Medical Uni-
versity of South Carolina (MUSC) Animal Review Com-
mittee and animals received humane care in compliance
with MUSC's experimental guidelines and the National
Research Council's criteria for humane care (Guide for the
Care and Use of Laboratory Animals).
Experimental groups
The animals were divided into three groups: i) Control
(sham), ii) Ischemia/reperfusion (Vehicle) and (iii)
Treated (treated with 5-LOX inhibitors). In the treatment
group, the rats were given 5-LOX inhibitor, dissolved in
sterile DMSO (15 μl) intravenously (IV) in the jugular
vein either before ischemia or at reperfusion. Three struc-
turally different 5-LOX inhibitors used were: BW-B 70C,
2.0 mg/kg 30 minutes before ischemia or 3.0 mg/kg at
reperfusion; AA-861, 3.0 mg/kg at reperfusion; caffeic
acid, 3.0 mg/kg of body weight at reperfusion. The rats inPage 2 of 13
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volume of DMSO alone.
Transient focal cerebral ischemia model
Rats were subjected to middle cerebral artery occlusion
(MCAO) as described previously [16,17] with slight mod-
ification. Briefly, rats were anesthetized with intraperito-
neal injection of xylazine (10 mg/kg body weight) and
ketamine hydrochloride (100 mg/kg). With the aid of a
dissecting microscope, the right common, internal and
external carotid arteries were exposed and the vagus nerve
separated carefully. Next the external carotid artery (ECA)
was isolated and ligated. A 4-0-monofilament nylon
suture (Harvard Apparatus, MA) was inserted through the
ECA into the internal carotid artery until a mild resistance
was felt, to occlude the middle cerebral artery (MCA) [18].
Animals were kept under constant conditions for 20 min-
utes of ischemia. At the end of the ischemic period, the
monofilament was withdrawn and the common carotid
artery clamp was removed. The animals were then
allowed to recover from anesthesia. During surgery, the
whole body temperature was maintained at 37.0 ± 0.5°C
using a heating pad, and monitored using a rectal temper-
ature probe.
Measurement of regional cerebral blood flow (CBF)
The occlusion of MCA and reperfusion were monitored by
measuring the regional CBF using laser Doppler flow
meter (Oxyflo, Oxford Optronics, England and Periflux
system 5000; Perimed Inc., Sweden). For measurement of
the blood flow, a needle-shaped laser probe was placed
over the skull (on right side) at 1 mm posterior and 4.0
mm lateral to the bregma. Baseline of CBF was obtained
before MCAO. CBF was monitored continuously during
ischemia (20 min) with a criterion of < 20% of baseline
blood flow remaining after MCAO. Reperfusion was con-
firmed by laser Doppler readings.
Measurement of physiologic parameters
The physiological variables were measured before and
after 30 min of reperfusion and are presented in Table 1.
The rectal temperature was monitored and maintained at
about 37 to 37.8°C. Body temperature was monitored by
a rectal probe and maintained at about 37 ± 0.5 °C by a
homeothermic blanket control unit (Harvard Apparatus,
Holliston, MA). Cranial temperature was measured by
HSE Plugsys TAM-D (Harvard Apparatus). Blood gases
and blood pH were measured by pH/blood gas analyzer
iSTAT (Heska, Fort Collins, CO). Mean blood pressure
(MBP) was measured using a XBP1000 NIBP system (Kent
Scientific, Torrington, CT). It is non-invasive computer-
ized tail-cuff system and uses automated inflation/defla-
tion pump. Blood glucose levels were measured in plasma
using Quantichrom glucose assay kit (Bioassay systems,
Haywood, CA).
Neurological evaluation
Neurological deficit in the animals was determined by an
observer blinded to the identity of the groups, and was
assessed at 24 h of reperfusion. The scoring was based on
method of Huang et al. [19] as follows: 0, no observable
neurological deficit (normal); 1, failure to extend left fore-
paw on lifting the whole body by tail (mild); 2, circling to
the contralateral side but normal posture at rest (moder-
ate); 3, leaning to the contralateral side at rest (severe); 4,
no spontaneous motor activity (very severe).
Measurement of ischemic infarct and image acquisition
Infarct volume was evaluated as previously described [17].
Briefly, after 24 h of reperfusion, the brains were quickly
removed and placed in ice-cold saline for 5 min and then
coronal sections were obtained at 2-mm intervals from
the frontal pole. The slices were incubated in 2% 2, 3, 5-
triphenyltetrazolium chloride (TTC) (Sigma, MO) dis-
solved in saline for 15 min at 37°C. The brain sections
were fixed by immersion in 10% formalin. The image of
Table 1: Physiologic parameters
Vehicle Caffeic acid AA-861 BW-B 70C
Basal 30 min Rep Basal 30 min Rep Basal 30 min Rep Basal 30 min Rep
Rectal Temp (°C) 37.2 ± 0.3 36.8 ± 0.2 37.6 +0.2 36.5 ± 0.3 37.4 ± 0.4 37.3 ± 0.2 37.3 ± 0.3 37.4 ± 0.2
Cranial Temp (°C) 37.0 ± 0.5 37.3 ± 0.7 36.8 ± 0.2 36.9 ± 0.3 37.4 ± 0.3 36.9 ± 0.4 36.9 ± 0.2 37.1 ± 0.4
PCO2 (mm Hg) 56.9 ± 7.6 55.7 ± 8.0 51.4 ± 9.2 52.4 ± 6.9 55.9 ± 9.0 53.8 ± 9.7 58.5 ± 6.4 52.6 ± 7.8
PO2 (mm Hg) 41.5 ± 7.8 44.0 ± 5.2 48.5 ± 8.2 39.5 ± 8.9 43.5 ± 8.4 37.0 ± 5.6 45.5 ± 6.3 38.5 ± 6.5
MBP (mm Hg) 106 ± 14 101 ± 10 102 ± 23 112 ± 10 109 ± 13 107 ± 12 117 ± 19 121 ± 14
Glucose (mg/dL) 190.5 ± 15.2 214.8 ± 18.6 210.5 ± 12.5 191.6 ± 12.9 201.8 ± 11.9 181.6 ± 16.8 190.5 ± 17.5 202.6 ± 10.9
PH 7.3 ± 0.1 7.3 ± 0.2 7.3 ± 0.1 7.3 ± 0.1 7.2 ± 0.2 7.3 ± 0.1 7.3 ± 0.1 7.3 ± 0.2
Measurements were performed before MCAO (base) and at 30 min of reperfusion after drug administration as described in Methods. All 
measurements other than temperature were performed in blood. Data are presented as mean ± SD for n = 3 in each group. Measurements were 
also performed for sham group. No significant differences were observed among the groups. Basal, 30 min before MCAO; MBP, mean blood 
pressure; Rep, reperfusion; Temp, temperaturePage 3 of 13
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tems) and quantified using Scion image image-analysis
software (Scion Corporation). The volume of infarction
was obtained from the product of average slice thickness
(2 mm) and sum of infarction area in all brain slices. Inf-
arct values were corrected for edema as described by Swan-
son et al [20]. Edema in this model contributed less than
10% of total infarction.
Immunohistochemistry
Protein expression was detected by immunohistochemi-
cal analysis. Paraffin embedded sections of brain tissues
were stained for 5-LOX, RCA-1 (Ricinus communis agglu-
tinin-1), GFAP (Glial fibrillary acidic protein), iNOS, p65
and NSE (Neuron-specific enolase). BV2 cells and rat pri-
mary microglia were stained for p65 protein expression.
In brief, the brain tissue sections were deparafinised and
rehydrated in sequential gradations of alcohol. After anti-
gen unmasking in unmasking solution (Vector Labs, CA),
sections were cooled and washed three times for two min-
utes each in PBS. Sections were immersed for 10 min in
3% hydrogen peroxide to eliminate endogenous peroxi-
dase activity and blocked in 1% bovine serum albumin for
1 hour. Sections were incubated overnight with respective
primary antibody (1:100 dilution in blocking buffer).
After washing in PBS containing 0.1% Tween-20, sections
were incubated with the appropriate fluorophore tagged
secondary antibody (1:100 dilution in blocking buffer)
(Vector Labs, CA). Fluorescence was visualized under the
microscope. All the sections were analyzed using a Zeiss
Olympus Microscope and images were captured using a
Kontron Digital Camera. At least ten different fields were
recorded for each measurement and a representative
image was presented in figures. Images were captured and
processed in Adobe Photoshop 7.0 (Adobe Systems, CA)
and were adjusted by using the brightness and contrast
level and unmasking tools to enhance image clarity.
Maintenance of cell lines and preparation of rat primary 
microglia
BV2 cells were maintained in DMEM (4.5 g glucose/L)
supplemented with 10% fetal FBS plus antibiotics and
induced with stimuli as indicated. The cell line was kindly
provided by Dr Michael McKinney of Mayo Clinic (Jack-
sonville, FL, USA). Primary microglia were prepared from
rat cerebral tissue as described previously [21]. Briefly,
after 10 days of culture, astrocytes were separated from
microglia and oligodendrocytes by shaking for 24 h in an
orbital shaker at 240 rpm. The microglia were plated onto
poly-lysine-coated plates for one hour, subsequently the
unattached cells were removed. For induction of nitric
oxide (NO), cells were stimulated with LPS under serum-
free conditions.
Assay for NO synthesis
NO production was determined in cell culture superna-
tants by measurement of nitrite, a stable reaction product
formed from released NO and molecular oxygen. Briefly,
100 μl of culture supernatant was made to react with 100
μl of Griess reagent and incubated at room temperature
for 15 minutes for optimal reaction product formation.
The absorbance of the assay samples was measured spec-
trophotometrically at 570 nm using SpectraMax 190
(Molecular Devices, CA). NO concentrations were calcu-
lated from a standard curve derived from the reaction of
NaNO2 (sodium nitrite) used as a standard in the assay.
Preparation of nuclear extracts
Nuclear extracts were prepared from treated and untreated
cells as described previously [22] based on modified
method of Dignam and coworkers [23]. At stipulated time
points after treatment, cells were harvested, washed twice
with ice-cold PBS. Cells were then lysed in 400 μl of buffer
A (containing: 10 mM HEPES, pH 7.9, 10 mM KCl, 2 mM
MgCl2, 0.5 mM dithiothreitol, 1 mM PMSF, 5 μg/ml apro-
tinin, 5 μg/ml pepstatin A, and 5 μg/ml leupeptin contain-
ing 0.1% Nonidet P-40) for 15 minutes on ice. Cells were
vortexed vigorously for 15 seconds, and then centrifuged
at 20,000 × g for 30 seconds. The pelleted nuclear fraction
was then resuspended in 40 μl of buffer B (20 mM HEPES,
pH 7.9, 25% (v/v) glycerol, 0.42 M NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 dithiothreitol, 1 mM PMSF, 5 μg/ml
aprotinin, 5 μg/ml pepstatin A, and 5 μg/ml leupeptin)
and kept on ice for 30 minutes. Lysates were centrifuged
at 20,000 × g for 10 minutes. Supernatants containing the
nuclear proteins were diluted with 20 μl of modified
buffer C (20 mM HEPES, pH 7.9, 20% (v/v) glycerol, 0.05
M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, and 0.5 mM
PMSF) and were processed for immunoblotting immedi-
ately or stored at -70°C until further use.
Immunoblot analysis
For immunoblotting, after incubation in the presence and
absence of stimuli, the cells were scraped off, washed with
Hank's buffer, and sonicated in 50 mM Tris-HCl (pH 7.4)
containing protease inhibitors (1 mM PMSF, 5 μg/ml
aprotinin, 5 μg/ml antipain, 5 μg/ml pepstatin A, and 5
μg/ml leupeptin). Proteins were resolved by SDS-PAGE
and transferred onto nitrocellulose membranes. The
membranes were blocked for 1 h in 5% nonfat dry milk
TTBS (20 mM Tris, 500 mM NaCl, and 0.1% Tween 20,
pH 7.5) and incubated overnight at 4°C in primary anti-
body containing 5% nonfat dry milk. The blots were then
washed four times with TTBS (5 min/wash) and incubated
for 45 minutes at room temperature with HRP-conjugated
secondary antibody at a dilution of 1:5000. The blots were
then washed three times in TTBS and once in 0.1 M PBS
(pH 7.4) at room temperature; the desired protein wasPage 4 of 13
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(Amersham Pharmacia Biotech).
Transfection studies
Transfection of cells was done as described previously [22].
Plasmids were purified using the endotoxin-free plasmid
midi-prep kit (Qiagen, Santa Clarita, CA, USA). For tran-
sient transfections, BV2 cells were seeded in 6-well plates
and grown to 60–80% confluence in DMEM medium with
5% FBS (without antibiotics), and were transfected using
FuGene reagent (Promega) with 1.5 μg of NF-κB-luc
reporter construct vector or insertless expression vector
(pBluescript). 24 h after transfection, cells were main-
tained in serum-free medium overnight and then treated
with LPS and/or BW-B 70C. Finally, 24 h later, luciferase
activity was measured in cell lysates prepared using lysis
buffer (Promega) as per the manufacture's protocol.
cDNA synthesis and real time PCR analysis
cDNA Synthesis and real time PCR analysis was carried
out with certain modifications of method described ear-
lier [24]. Total RNA from brain tissue was isolated using
Trizol reagent (Gibco BRL, Carlsbad, CA) as per manufac-
turer's instructions. Single-stranded cDNA was synthe-
sized from pooled RNA samples of rat brains from three
similarly treated rats by using the superscript preamplifi-
cation system (Life Technologies, Carlsbad, CA). Quanti-
tative real-time PCR was performed with the Bio-Rad
(Hercules, CA) iCycler iQ Real-Time PCR Detection Sys-
tem as per conditions described previously [24]. Briefly,
primer sets were designed and synthesized from Inte-
grated DNA Technologies (IDT, Coralville, IA). The
primer sequences were: GAPDH, forward primer, 5'-cctac-
ccccaatgtatccgttgtg-3', reverse primer, 5'-ggaggaatgggagtt-
gctgttgaa-3'; iNOS, forward primer, 5'-
ggaagaggaacaactactgctggt-3', reverse primer, 5'-gaactgaggg-
tacatgctggagc-3'. Thermal cycling conditions were as fol-
lows: activation of iTaq DNA polymerase at 95°C for 10
minutes, followed by 40 cycles of amplification at 95 °C
for 30 seconds and 55–57.5°C for 1 minute. The normal-
ized expression of target gene with respect to GAPDH was
computed for all samples by using Microsoft Excel data
spreadsheets.
Statistical analysis
Statistical analysis was performed using software Graph-
pad Prism 3.0, unless stated otherwise. Values are
expressed as mean ± SD of n determinations or as men-
tioned. Comparisons among means of groups were made
with a two-tailed Student's t-test for unpaired variables.
Multiple comparisons were performed using one-way
ANOVA followed by Bonferroni test. p values less than
0.05 were considered significant.
Results
Treatment with 5-LOX inhibitors improves brain infarction 
and neurological score after IR injury
Pretreatment with 5-LOX inhibitor BW-B 70C (2 mg/kg)
reduced infarct volume and improved neurological deficit
score (Fig. 1A–C) recorded at 24 h reperfusion after 20 min
MCAO in rats. The animals were monitored for changes in
regional CBF before during and after occlusion (Fig. 1D).
Changes in the CBF were not significantly different after
ischemia between the untreated (vehicle) and BW-B 70C
treated groups. CBF measurements indicated that all rats
were subjected to a similar degree of ischemia (>80% drop
in CBF compared to baseline). Fig. 1A shows representative
TTC stained sections from sham; vehicle and BW-B 70C
treated animals, showing that the treatment reduced infarc-
tion. As seen in Fig. 1B, BW-B 70C treated animals had
reduced infarct volume 215.0 ± 35.0 mm3 compared with
vehicle group (512.2 ± 30.5 mm3). Furthermore, significant
neuroprotection was observed even when BW-B 70C (3 mg/
kg) was administered at the time of reperfusion after
ischemia (infarct volume: 205.2 ± 8.9 mm3) as shown in
Table 2A. Other structurally different 5-LOX inhibitors, caf-
feic acid and AA-861, provided similar degrees of protection
when administered at the time of reperfusion. They reduced
the infarct volumes to 229.5 ± 18.5 and 210.4 ± 20.5,
respectively (Table 2A). Neurological deficit scores were
evaluated at 24 h after reperfusion (Fig. 1C and Table 2B),
and were consistent with the changes observed in infarct
volume. Pre-treatment with BW-B 70C improved the neuro-
logical score to median1.0 compared to the vehicle group
median 3.0, (Fig. 1C). Even after ischemia, treatment with
5-LOX inhibitors reduced neurological score to median1.0
compared to the vehicle group (median 3.0) as shown in
Table 2B. The use of an effective dose of 5-LOX inhibitors is
based on maximal brain protection (infarct volume) at low-
est dose determined from a study carried out separately for
each inhibitor. Administration of either 2 mg/kg or 3 mg/kg
of BW-B 70C prior to ischemia had similar effect on reduc-
tion of infarctions. However, the treatment with 2 mg/kg
BW-B 70C after ischemia was less effective compared to 3
mg/kg. The selected dose had no significant effects on phys-
iologic parameters (blood gases, cranial temperature, mean
blood pressure, blood glucose and pH) as shown in Table 1.
Postmortem studies have shown that brain sections from
stroke patients are positive for 5-LOX expression [7]. To
investigate the increased expression of the 5-LOX enzyme
after IR injury, and whether administration of BW-B 70C
reduces the 5-LOX expression, we subjected rat brain tis-
sue sections to immunohistochemistry (Fig. 1E, a–c).
There was increased expression of 5-LOX in the ipsilateral
hemisphere of brain tissue sections at 24 h after reper-
fusion (Fig. 1E, b), which was reduced by the administra-
tion of BW-B 70C (Fig. 1E, c). The mechanisms of 5-LOXPage 5 of 13
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Pretreatment with BW-B 70C protects the brain from infarction and improves neurological scoreFigure 1
Pretreatment with BW-B 70C protects the brain from infarction and improves neurological score. (A) Photo-
graph showing effect of BW-B 70C on TTC-stained sections, (B) Effect of BW-B 70C on infarct volume (measured in six serial 
coronal sections arranged from cranial to caudal regions), (C) Effect of BW-B 70C on neurological score and (D) Effect of BW-
B 70C on regional cerebral blood flow (CBF). Changes in CBF were not significantly different after ischemia between the 
untreated (vehicle) and treatment (BW-B 70C) groups. (E) Photomicrograph of expression of 5-LOX (n = 4) at 24 h reper-
fusion after 20 min MCAO (magnification X200). Data for infarct volume (n = 7) and blood flow (n = 4) are presented as means 
± SD. *p < 0.001 vs. vehicle. Data for neurological deficit score (n = 7) are presented as individual data points.
Journal of Neuroinflammation 2006, 3:12 http://www.jneuroinflammation.com/content/3/1/12inhibition by a non-redox type inhibitor BW-B 70C are
not clear.
Co-localization of 5-LOX expression in neurons and
microglia/macrophage in brain after IR injury.As inferred
from the data above (Fig. 1E, a–c), there is an increase in
the expression of 5-LOX enzyme after IR injury. To deter-
mine the cellular localization of 5-LOX expression, sec-
tions from ischemic brain after 24 h of reperfusion were
subjected to immunohistochemistry with antibody
against 5-LOX. 5-LOX expression co-localized with NSE, a
neuron specific marker, implying that 5-LOX protein
expression was increased in neurons after IR (Fig. 2c). The
expression also co-localized in the microglia/macrophage,
as seen by merging the 5-LOX and microglia/macrophage
antigen RCA-1 (Fig. 2i). RCA-1 is not a widely used anti-
gen for microglia. However, Rezaie et. al. have lately
described this antigen as specific to microglia, detecting
both developing and resting adult microglia [25]. A co-
localization study of 5-LOX and GFAP, a marker for acti-
vated astrocytes, showed a few 5-LOX/GFAP positive cells
(Fig. 2f). These observations indicate that 5-LOX protein
is up regulated mainly in microglia/macrophage and neu-
rons in the ipsilateral hemisphere after IR injury.
Inhibition by BW-B 70C of iNOS protein expression and 
p65 translocation in brain after IR injury
As concluded from the data above (Figs. 1E and 2), there
is an increased expression of 5-LOX enzyme in the brain
after IR injury. Growing evidence suggests that 5-LOX and
iNOS communicate and regulate the signaling cascade of
inflammatory gene expression [11,26]. BW-B 70C treat-
ment reduced the IR injury-induced inflammatory
5-LOX is expressed in neurons and microglia/macrophagesFigure 2
5-LOX is expressed in neurons and microglia/macro-
phages. Co-localization of expression of (a) NSE, (d) GFAP; 
(g) RCA; and 5-LOX (b,e,h) at 24 h reperfusion after 20 min 
MCAO. Yellow fluorescence indicates co-localization of 5-
LOX/NSE (c) and 5-LOX/RCA (i). 5-LOX/GFAP (f) showed 
very few yellow-fluorescent structures. Figures are repre-
sentative of similar results obtained from three different sec-
tions of three different animals in each group (Magnification 
400 ×).
Table 2: Infarct volume, infarct area and neurological score in untreated (vehicle) and 5-LOX inhibitor-treated rats at 24 h reperfusion 
after 20 min MCAO. 
Group N Infarct volume (mm3) Infarct area (%)
A. Infarct volume and 
infarct area
Vehicle 7 522.5 ± 11.2 41.3 ± 10.5
Caffeic acid 7 229.5 ± 18.5* 12.8 ± 1.9*
AA-861 7 210.4 ± 20.5* 11.3 ± 2.9*
BW-B 70C 7 205.2 ± 8.9* 11.8 ± 2.1*
B. Neurological Score Number of animals = 7
Vehicle Caffeic acid AA-861 BW-B 70C
Frequencies
0 0 0 0 0
1 0 4 4 5
2 0 3 2 2
3 6 0 1 0
4 1 0 0 0
Median 3 1 1 1
Infarct volume and infarct area (A) and neurological deficit score (B) were measured at 24 h of reperfusion after 20 min MCAO. Animals were 
treated either with 5-LOX inhibitors dissolved in DMSO alone (vehicle) at reperfusion as described in Methods. Data in Table B represent number 
of animals showing corresponding neurological score (ranging from 0 to 4 as detailed in Methods). Data are expressed as mean ± SD for infarct area 
and infarct volume and as range and median for neurological deficit score. *p < 0.001 vs. vehicle.Page 7 of 13
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via inhibition of iNOS gene expression (Fig. 3B). This
gene expression was quantified by real time PCR analysis
of mRNA 3 h after reperfusion.
Activation of NF-κB is involved in iNOS gene expression
and is associated with the translocation of p50:p65 het-
erodimer into the nucleus. BW-B 70C prevented nuclear
translocation of p65 subunit in vivo, as demonstrated by
immunohistochemistry (Fig. 3C, iii). Taken together,
these data suggest that BW-B 70C leads to down-regula-
tion of iNOS gene expression by inhibiting p65 transloca-
tion to the nucleus.
BW-B 70C attenuates LPS-mediated expression of iNOS 
and levels of NO in BV2 microglial cell line
It has been documented that iNOS-derived NO from
microglia/macrophages contributes to the pathobiology
of cerebral IR injury [27]. Earlier we showed that glial
cells, specifically microglia, produce NO in response to
induction of iNOS by LPS and cytokines [28]. NO pro-
duced by iNOS has been shown to contribute to neuronal
death in neurogenerative diseases [29]. Furthermore,
growing evidence suggests the role of 5-LOX in induction
of inflammatory genes [30]. Therefore, we examined the
role of 5-LOX in the regulation of iNOS expression in glial
cells in vitro.
BW-B 70C was not toxic up to 75 μM concentration as
assessed in vitro by MTT assay (data not shown). The other
selective 5-LOX inhibitor, AA-861 was found to be toxic at
50–75 μM concentrations and caused cell death. MTT
assays were not performed on caffeic acid-treatment
experiments because, while it is a potent 5-LOX inhibitor,
it is not selective. Hence, we used BW-B 70C in cell culture
experiments.
Treatment with BW-B 70C (up to 75 μM) attenuated NO
production measured as nitrite (Fig. 4A) and iNOS pro-
tein expression (Fig. 4B) quantified by immunoblot anal-
ysis in LPS-treated cells. These data suggest that 5-LOX
inhibition lead to the down-regulation of iNOS expres-
sion.
BW-B 70C attenuates LPS-mediated expression of NF-κB 
luciferase activity in BV2 microglial cells
Because the activation of NF-κB is important for the
induction of iNOS in glial cells [31], the effect of BW-B
70C on the activation of NF-κB was examined in BV2
cells. BW-B 70C inhibited the LPS-mediated NF-κB-
dependent luciferase activity in a dose-dependent manner
(Fig. 5A).
To confirm further the inhibition of NF-κB by BW-B 70C,
we examined the effect of BW-B 70C on nuclear transloca-
tion of p50/p65 complex in LPS-treated primary micro-
glial cells. LPS stimulated the nuclear translocation of p65
and p50 subunits to the nucleus, and the translocation
was prevented by BW-B 70C treatment (Fig. 5B–C). The
observation was confirmed by immunocytochemical
analysis (Fig. 5D). These results indicate that inhibition of
5-LOX prevents nuclear translocation of p50/p65 com-
plex, which may cause down-regulation of NF-κB activity.
BW-B 70C inhibits expression of iNOS and p65 in vivoFigure 3
BW-B 70C inhibits expression of iNOS and p65 in 
vivo. (A) Photomicrographs of immunohistochemistry of rat 
brain sections at 24 h reperfusion after 20 min MCAO show-
ing remarkable iNOS expression in vehicle-treated (ii) but 
not in BW-B 70C-treated rats (iii). (B) BW-B 70C inhibited 
IR-induced iNOS gene expression measured as mRNA levels 
at 3 h of reperfusion after 20 min MCAO. The results are 
presented as mean ± SD of normalized expression of target 
gene with respect to GAPDH mRNA from three sets of ani-
mals. (C) Treatment with BW-B 70C prevented the nuclear 
translocation of p65 subunit of NF-κB (i-iii); the vehicle-
treated animals showed nuclear translocation (ii) and treat-
ment with BW-B 70C reversed this (iii) at 24 h reperfusion 
after 20 min MCAO. Figures are representative of similar 
results obtained from three groups of animals. A (i-iii) magni-
fication 100 X; C (i-iii) magnification 200 X. *p < 0.01 vs. 
vehicle (n = 3).Page 8 of 13
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Brain damage caused by IR is due, in part, to secondary
injury from inflammation [32]. The degree of inflamma-
tion is exacerbated by increased lipid peroxidation which
increases neuronal death [33]. Leukotrienes derived from
the metabolism of arachidonic acid by the 5-LOX enzyme
are potent inflammatory mediators in IR injury [34].
Recently, 5-LOX has been shown to be involved in
ischemic-like injury in neuronal PC12 cells [35]. As in
human brain following stroke [7], we found increased
expression of 5-LOX after IR in rat brain neurons and
microglia/macrophage (Fig. 2).
Many substituted N-hydroxyureas, including BW-B 70C
and Zileuton, are well-known potent and selective inhibi-
tors of 5-LOX [36,37]. BW-B 70C has a long half-life and
high oral bioavailability. Zileuton, an anti-leukotriene
drug, has been identified as an anti-inflammatory com-
pound [38] and is currently undergoing clinical trials in
patients suffering from diseases in which leukotrienes
play a pathogenic role [39]. To further support the idea
that 5-LOX inhibition provides significant neuroprotec-
tion in experimental stroke, we used other well-estab-
lished 5-LOX inhibitors, (caffeic acid and AA-861). The
three 5-LOX inhibitors used in this study are structurally
different. All were highly protective, reduced infarction
and improved neurological deficit score (Fig. 1A–C and
Table 2). 5-LOX inhibitors are therefore neuroprotective
irrespective of their structural identities. BW-B 70C may
be safer as a therapeutic agent due to the toxicity (cell via-
bility assay using MTT) associated with AA-861 in vitro
(data not shown). Furthermore, BW-B 70C may show
greater potential in humans due to its structural similarity
to Zileuton, high oral bioavailability and longer half life.
In our studies, we have used a focal cerebral ischemia ani-
mal model involving transient MCAO followed by reper-
fusion [28]. This model closely reproduces clinical
ischemic brain damage, showing the oxidative stress and
the inflammation observed in human ischemic stroke
patients [40]. To test whether secondary inflammatory
injury can be reversed by 5-LOX inhibitors, we selected a
model with short-term (20 min) MCAO (with ~80% drop
in CBF compared to basal value Fig. 1D) followed by
reperfusion. In this model, there was more significant
inflammatory response than cell death, which is appropri-
ate to determine the efficacy of anti-inflammatory drugs
[28].
BW-B 70C inhibits LPS-mediated iNOS expression in BV2 cellsFigure 4
BW-B 70C inhibits LPS-mediated iNOS expression in BV2 cells. (A) BV2 Cells were pretreated for 30 min with dif-
ferent concentrations of BW-B 70C followed by LPS (1 μg/ml) treatment. After 24 h, NO as nitrite was quantified in superna-
tant by Griess reagent. Data are presented as means ± SD for 3 different experiments. (B) Cell lysates were processed for 
western blot analysis of iNOS and β-actin after 24 h of stimulation with LPS (1 μg/ml). Figures are representative of 3 different 
experiments. *p < 0.001 vs. LPS; **p < 0.001 vs. LPS+25 μM BW-B70C; ***p < 0.001 vs. LPS+25 μM BW-B70C; +p < 0.001vs 
LPS + 50 μM BW-B 70C.Page 9 of 13
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BW-B 70C inhibits LPS-induced NF-κB activation in microglial BV2 cells and prevents nuclear translocation of p65 in rat pri-mary microgliaFigure 5
BW-B 70C inhibits LPS-induced NF-κB activation in microglial BV2 cells and prevents nuclear translocation of 
p65 in rat primary microglia. (A) Microglial cells (BV2) were transiently co-transfected with 1.5 μg of NF-κB luciferase 
reporter construct. Cells were pre-treated with BW-B 70C (25–75 μM) for 30 min followed by LPS (1 μg/ml) stimulation for 4 
h. Luciferase activity was normalized with respect to β-galactosidase activity. Data are means ± SD of three different experi-
ments. Immunoblot was performed at 1 h post treatment with LPS (1 μg/ml) for p65 (B) and p50 (C) in nuclear extract from 
primary microglia. A non-specific band (NS) was taken as internal standard. Blots are representative of three different experi-
ments. (D) Immunohistochemcal analysis of rat primary microglia showing nuclear translocation of p65 1 h post LPS treatment. 
Cells were pretreated with BW-B 70C (75 μM) for 30 min before stimulation with LPS (1 μg/ml). Red fluorescence shows pos-
itive reaction for p65 and blue fluorescence showed nuclear staining with DAPI. LPS treatment translocated p65 to the nucleus, 
and treatment with BW-B 70C reversed it. Figures are representative of 3 experiments. (Magnification 200 X). #p < 0.001 vs. 
untreated; *p < 0.001 vs. untreated; **p < 0.001 vs. LPS; ***p < 0.001 vs. LPS+BW-B 70C (50 μM).
Journal of Neuroinflammation 2006, 3:12 http://www.jneuroinflammation.com/content/3/1/12NF-κB is one of the key regulators of inflammation. In
brain ischemia, its roles in both cell survival and cell death
have been shown [41]. Recently, Zhang et al [42] docu-
mented that activation of NF-κB in neurons is deleterious
in cerebral ischemia. In addition, the NF-κB pathway has
been shown to be instrumental in up-regulation of iNOS
and of other inflammatory mediators that are damaging
in stroke [28]. Inhibition of iNOS expression in micro-
glia/macrophage by antioxidants has been shown to pro-
tect the brain after IR injury [43]. We demonstrated in this
study that IR injury caused an increased expression of 5-
LOX, NF-κB and iNOS. The attenuation of expression of
these inflammatory mediators by 5-LOX inhibitors
resulted in neuroprotection as seen by decreased infarc-
tion size and improved neurological deficit scores (Fig.
1A–C and Table 2). These inhibitors did not significantly
alter physiologic parameters as shown in Table 1.
The critical aspect of 5-LOX/NF-κB signaling may be its
direct interaction with the p65 subunit of NF-κB [14]. It
has been reported that NF-κB activation occurs via 5-LOX-
mediated generation of ROS in lymphoid cells [9]. How-
ever, the mechanisms of NF-κB activation by direct inter-
action with 5-LOX remain to be investigated. The 5-LOX
inhibitor BW-B 70C used in this study inhibited NF-κB
luciferase activity in vitro (Fig. 5A). It also inhibited p65
translocation to nucleus both in vitro (Fig 5B and 5D) and
in vivo (Fig. 3C, iii). Furthermore, BW-B 70C reduced
iNOS expression in vitro (Fig. 4B). We hypothesize that 5-
LOX action is upstream to NF-κB, and its inhibition
results in reduced expression of NF-κB and iNOS, thereby
ameliorating inflammation.
The 5-LOX-leukotriene pathway has been implicated in
aneurysm formation [44]. The present study accords with
other studies showing neuroprotective effects against
inflammation-mediated injury [45]. Inhibition of phos-
pholipase A2 (PLA2), the enzyme that liberates arachi-
donic acid from membrane phospholipids, provides
limited protection in stroke because the metabolism of
polyunsaturated fatty acids (PUFA) is required to generate
several anti-inflammatory eicosanoids [46] and epoxides
[47]. The COX-2 pathway has been documented as a val-
uable therapeutic target for ischemic brain injury [48,49].
However, it is also recognized that chronic inhibition of
this pathway produces an eicosanoid synthesis imbalance
that promotes undesirable vascular effects [50]. Further-
more, the inhibition of the COX-2 pathway would result
in the bioavailability of PLA2-derived PUFAs to lipoxyge-
nases. This may result in excessive production of leukot-
rienes and the generation of ROS. Increased leukotriene
production results in depletion of GSH, thus making cells
vulnerable to ROS injury [51]. Inhibiting the 5-LOX/NF-
κB pathway has potential to circumvent the problems
associated with blocking PLA2 or the COX-2 pathway.
However, it has been demonstrated that 5-LOX knock out
mice do not show protection during IR [52]. In this con-
text, we hypothesize that 5-LOX expression modulates
multiple events, and its role may become evident only
under pathological conditions. Further, a certain basal
activity of the enzyme may be required physiologically,
and the complete depletion of the enzyme is detrimental,
as is the case with TNF-α knock out mice [53].
Conclusion
This study demonstrates the protective effect of 5-LOX
inhibitors when administered either prior to ischemic
insult or at reperfusion in a rat model of experimental
stroke. The protective effect of 5-LOX inhibitors is due in
part to down-regulation of iNOS via inhibition of NF-κB
activation. Acute stroke is a multi-component inflamma-
tory disorder, and its treatment will involve agents antag-
onizing multiple mechanisms of inflammation.
Therefore, we propose that 5-LOX inhibitors may have
therapeutic potential to treat neuroinflammation in
ischemic stroke injury.
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